Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: trabectedin Clear all
Completed Phase 2 Interventional Results available

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

NCT00147212
View directory record Official record
Conditions
Prostate Cancer
Interventions
ET 743
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 20, 2026, 11:43 PM EDT
Withdrawn Phase 2 Interventional

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

NCT03397186
View directory record Official record
Conditions
Myxoid Liposarcoma, Round Cell Liposarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Interventions
Biopsy, Laboratory Biomarker Analysis, Trabectedin
Procedure · Other · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

NCT00796120
View directory record Official record
Conditions
Sarcoma
Interventions
Trabectedin, Doxorubicin, Ifosfamide
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Santa Monica, California • Boston, Massachusetts • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 2 Interventional

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

NCT00580112
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Dexamethasone, Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
21
States / cities
Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 20, 2026, 11:43 PM EDT
Withdrawn Phase 1 Interventional

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

NCT03884972
View directory record Official record
Conditions
Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Trabectedin, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

NCT01273480
View directory record Official record
Conditions
Neoplasm Metastases
Interventions
Sequence 1, Sequence 2
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 20, 2026, 11:43 PM EDT
Recruiting Phase 2 Interventional

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

NCT04535271
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

NCT00070109
View directory record Official record
Conditions
Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor
Interventions
trabectedin, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Madera, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer

NCT00072670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

NCT00050440
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 20, 2026, 11:43 PM EDT
Terminated Phase 2Phase 3 Interventional

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

NCT01189253
View directory record Official record
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

NCT00579501
View directory record Official record
Conditions
Liposarcoma,Myxoid
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Coeur d'Alene, Idaho • Park Ridge, Illinois • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 3 Interventional Results available

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

NCT01343277
View directory record Official record
Conditions
Advanced Liposarcoma or Leiomyosarcoma
Interventions
Trabectedin, Dacarbazine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
15 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
77
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

NCT00060944
View directory record Official record
Conditions
Liposarcoma, Leiomyosarcoma
Interventions
Yondelis, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
20
States / cities
Los Angeles, California • Aurora, Colorado • Coeur d'Alene, Idaho + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 1 Interventional

Tabectedin to Treat Children and Adolescents With Cancer

NCT01453283
View directory record Official record
Conditions
Solid Tumors
Interventions
Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 1 Interventional

Ecteinascidin 743 in Treating Children With Refractory Solid Tumors

NCT00006463
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ECTEINASCIDIN 743
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
42
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

NCT00569673
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, pegfilgrastim, docetaxel, trabectedin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
37
States / cities
Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 20, 2026, 11:43 PM EDT
Recruiting Phase 1 Interventional

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

NCT07444619
View directory record Official record
Conditions
Soft Tissue Sarcomas
Interventions
Pazopanib, Trabectedin, Ipilimumab, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 11:43 PM EDT
Completed Phase 1Phase 2 Interventional

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

NCT04067115
View directory record Official record
Conditions
Ewing Sarcoma
Interventions
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Drug · Diagnostic Test · Other
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
6 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 20, 2026, 11:43 PM EDT
Active, not recruiting Phase 1 Interventional

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

NCT05352750
View directory record Official record
Conditions
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Interventions
SON-1010
Biological
Lead sponsor
Sonnet BioTherapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 20, 2026, 11:43 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

NCT04979442
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
RAIN-32, Trabectedin
Drug
Lead sponsor
Rain Oncology Inc
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Palo Alto, California • Santa Monica, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 20, 2026, 11:43 PM EDT
Terminated Phase 2 Interventional

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

NCT00027508
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
trabectedin
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 20, 2026, 11:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231
View directory record Official record
Conditions
Sarcoma,Soft Tissue
Interventions
INT230-6, Eribulin, Trabectedin, Pazopanib
Drug
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 20, 2026, 11:43 PM EDT
No Longer Available No phase listed Expanded access

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

NCT00210665
View directory record Official record
Conditions
Sarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 20, 2026, 11:43 PM EDT